



Press Release, June 25, 2018

LIDDS' NanoZolid® technology recognized through publication of scientific article in *Journal of Drug Delivery Science and Technology*

The international *Journal of Drug Delivery Science and Technology* will publish the scientific article in the August edition titled “Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release formulations”.

The NanoZolid® technology has, over the course of several years, demonstrated its ability to enable a controlled release of a wide range of drugs following a single parenteral injection, resulting in stable and pharmacologically relevant plasma exposure levels over the desired time period. LIDDS has a number of active projects for the intratumoral treatment of cancer and also for the use of NanoZolid® technology as a subcutaneous depot to achieve sustained and controlled systemic drug release.

“The article describes the fundamentals and versatility of the NanoZolid® technology and will strengthen the international recognition of NanoZolid®, a patented and innovative technology platform suitable for many different types of drugs and for both intratumoral and subcutaneous administration,” says Monica Wallter, CEO of LIDDS.

NanoZolid® formulations for intratumoral drug delivery enables a high drug load and efficacy in cancer tumors combined with small risks for systemic adverse effects resulting in increased quality of life for cancer patients.

NanoZolid® formulated drugs for subcutaneous systemic release can overcome issues with frequent treatments and low compliance, giving patients and healthcare providers new and innovative treatment options. There is a significant need for this type of technology in a wide range of disease areas, for example in psychiatric, endocrine and inflammatory diseases.

LIDDS collaborates with Karolinska Institutet for the research and development of new NanoZolid®-based drug formulations.

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. For more information, please visit liddspharma.com.

LIDDS AB (publ) Org nr: 556580-2856, Virdings allé 32B, 754 50 Uppsala 0737-07 09 22 www.lidds.se